Mohalkar Krushna*
Dr. Tarde Vijay
Dahatonde Abhijit
Munfan Sumit
Cyclophosphamide (CTX) belongs to a class of cytotoxic alkylating nitrogen mustard chemicals, and is also marketed under the trade names ENDOXAN®, CYTOXAN®, ROCYTOX®, and NEOSAR®. The amount of CTX given in animal models and in humans varies according on the treatment objective and plan. Due to its selective cytotoxicity on lymphocytes without being myeloablative, high-dose CTX therapy (≥200 mg/kg) was originally developed as a conditioning regimen for allogeneic bone marrow transplantation to prevent graft-versus-host disease (GvHD).[1] One of the greatest anti-cancer medications ever created is cyclophosphamide. Even fifty years after its invention, it is still widely used in chemotherapy and in the conditioning and mobilization procedures for blood and marrow transplantation (BMT). Cyclophosphamide was found to be the most effective molecule after testing 1,000 chosen compounds and antibiotics against 33 tumors. In 1958, the first clinical trials of cyclophosphamide for the treatment of cancer were carried out, and in 1959, the FDA authorized it as the eighth cytotoxic anticancer drug. [6]
10.5281/zenodo.17682329